pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›YESAFILI
drug · protein
save

YESAFILI

Marketedupdated 6mo ago
by $HCWB HCW Biologics Inc.🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • drugEYLEA HD18 co-mentions · 7 sources
  • tagApproval18 co-mentions · 7 sources
  • drugEylea14 co-mentions · 7 sources
  • drugaflibercept biosimilar9 co-mentions · 7 sources
  • companyBiocon Biologics Ltd4 co-mentions · 2 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 16 approved and 39 investigational indications.

targets

Placenta growth factorVascular endothelial growth factor A, long form

all catalysts(2)

approval · 2
May 20, 2024
approval
$HCWB
3y ago
YESAFILI (AFLIBERCEPT-JBVF) — FDA approval
YESAFILI
→
Jan 13, 2026
approval
$HCWB
10mo ago
YESAFILI (AFLIBERCEPT-JBVF) — FDA approval
YESAFILI
→

News(10)

  • J&J bets $2.2B on Ollin’s vision loss drug
    The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
    biopharma_dive · 2d ago
  • J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
    Johnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.
    fiercebiotech · 3d ago
  • Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
    AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.
    biopharma_dive · 16d ago
  • Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
    Regeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…
    biospace · 19d ago
  • EyePoint will halve workforce, end pivotal wet AMD trials early following second fail
    EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shiftin…
    biospace · 1mo ago
  • This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
    The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
    biopharma_dive · 1mo ago
  • Lilly, Foghorn part ways; Wave’s FDA-approved plans
    The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
    biopharma_dive · 1mo ago
  • Kodiak skyrockets on positive study data for 2 eye drugs
    The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
    biopharma_dive · 1mo ago
  • Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
    Kodiak Sciences appears to have an Eylea successor on its hands. The Silicon Valley biotech said its experimental drug Zenkuda performed as well as Eylea in a progressive eye disease known as wet a…
    endpoints · 1mo ago
  • Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
    Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.
    biospace · 1mo ago
view all news mentions →
brand
YESAFILI
trade names
Eylea, Yesafili, Zaltrap
generic
AFLIBERCEPT-JBVF
MOA
Placenta growth factor inhibitor; Vascular endothelial growth factor A inhibitor
indication
glaucoma
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?